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Global Review of the Age Distribution of Rotavirus 
Disease in Children Aged <5 Years Before the Introduction 
of Rotavirus Vaccination
Mateusz Hasso-Agopsowicz,1,2,a,  Chandresh Nanji Ladva,3,a Benjamin Lopman,3 Colin Sanderson,1 Adam L. Cohen,2 Jacqueline E. Tate,4 Ximena Riveros,2 
Ana Maria Henao-Restrepo,2 and Andrew Clark1; in collaboration with the Global Rotavirus Surveillance Network and Rotavirus Age Study Collaborators
1London School of Hygiene and Tropical Medicine, United Kingdom; 2World Health Organization, Geneva, Switzerland; and 3Emory University, and 4Centers for Disease Control and Prevention, 
Atlanta, Georgia
We sought datasets with granular age distributions of rotavirus-positive disease presentations among children <5 years of age, before 
the introduction of rotavirus vaccines. We identified 117 datasets and fit parametric age distributions to each country dataset and 
mortality stratum. We calculated the median age and the cumulative proportion of rotavirus gastroenteritis events expected to occur 
at ages between birth and 5.0 years. The median age of rotavirus-positive hospital admissions was 38 weeks (interquartile range 
[IQR], 25–58 weeks) in countries with very high child mortality and 65 weeks (IQR, 40–107 weeks) in countries with very low or low 
child mortality. In countries with very high child mortality, 69% of rotavirus-positive admissions in children <5 years of age were in 
the first year of life, with 3% by 10 weeks, 8% by 15 weeks, and 27% by 26 weeks. This information is critical for assessing the potential 
benefits of alternative rotavirus vaccination schedules in different countries and for monitoring program impact.
Keywords. vaccine; rotavirus; rotavirus gastroenteritis; age distribution.
Rotavirus gastroenteritis (RVGE) is estimated to cause approx-
imately 200 000 child deaths each year [1]. More than half of 
the countries in the world now include live oral rotavirus vac-
cines in their national immunization programs [2]. There are 
4 vaccines licensed for global use (Rotarix, GlaxoSmithKline; 
RotaTeq, Merck & Co; ROTAVAC, Bharat Biologicals; and 
ROTASIIL, Serum Institute of India), others for national use 
(eg, in Vietnam, China), and several others in the pipeline, 
including neonatal and nonreplicating injectable vaccines [3]. 
Rotavirus vaccines are currently coadministered with other vac-
cines that are already part of the routine immunization sched-
ule. Most high-mortality countries use Rotarix, administered in 
2 doses at 6 and 10 weeks of age. However, there is variation in 
the brand of vaccine used, as well as the target number of doses, 
target ages, and actual coverage and timeliness of each dose. 
The World Health Organization (WHO) recommends admin-
istering the first dose from 6 weeks of age, with an interval of 
at least 4 weeks between doses [4]. Randomized controlled 
trials have reported high vaccine efficacy (~90%) against severe 
RVGE in low-mortality countries but modest efficacy (~50%) 
in higher-mortality settings [5]. Alternative schedules are being 
considered to increase their impact. A neonatal vaccine has had 
promising results in Indonesia [6], and some studies have evalu-
ated the potential of a booster dose given at around 9–12 months 
of age [7, 8]. Several studies and surveillance systems have col-
lected information on RVGE age distributions, but much of it 
is unpublished or has been published in age bands that are too 
broad to allow a detailed assessment of the potential impact of 
alternative rotavirus vaccination schedules. More granular age 
distributions would also help to quantify the number of RVGE 
cases expected to occur at specific ages, so that changes can be 
monitored after vaccination. More generally, there is a need to 
update the global evidence on RVGE age distributions, compare 
them between countries and regions, and establish a reliable 
method for extrapolating them to countries without data. An 
unpublished review was conducted in 2012 [9], but this did not 
include the large multicountry Global Rotavirus Surveillance 
Network (GRSN) database [10], and several pivotal multicoun-
try studies have also been published since [11–13].
In this article, we aim to estimate granular age distributions 
of rotavirus disease outcomes in children aged <5 years by type 
of RVGE presentation, country, and mortality level, before the 
introduction of rotavirus vaccines. This article does not gen-
erate estimates of the potential impact of alternative rotavi-
rus vaccination schedules but does provide inputs that will be 
important for those calculations.
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METHODS
Ethical Approval
This study was approved by the ethical committee of the 
London School of Hygiene and Tropical Medicine (ethics refer-
ence number 14398). All authors and countries gave their con-
sent to analyze and publish the data.
Search Strategy and Study Selection
We sought country datasets containing counts of rotavirus-pos-
itive disease in children aged <5 years before the introduction 
of rotavirus vaccines. A country dataset is defined as a dataset 
derived from a single study (eg, hospital surveillance, case-con-
trol, cohort) within a single country, reporting on a single rota-
virus-positive outcome/presentation (community cases, clinic 
visits, emergency visits, hospitalizations, deaths). If a data-
set contained multiple subnational locations and/or multiple 
calendar years, then these were aggregated, and any relevant 
exclusion criteria were applied to the aggregated dataset. When 
studies reported multiple rotavirus-positive presentations, each 
presentation was considered to be a distinct dataset. Prevaccine 
datasets only included data for years prior to rotavirus vaccine 
introduction.
First, we analyzed the WHO GRSN database, which con-
tains information about hospital admissions among children 
aged <5  years from surveillance sites in 69 countries [10]. In 
these sites, rotavirus positivity is determined by enzyme immu-
noassay (EIA). We applied the definition described above and 
aggregated subnational locations and multiple calendar years to 
create unique prevaccine introduction GRSN country datasets. 
The year of rotavirus vaccine introduction was determined by 
WHO/United Nations Children’s Fund (UNICEF) estimates of 
national immunization coverage [14]. If a country dataset did 
not have data on hospital admissions by day of age, then we 
used month of age. Admissions recorded as aged zero days were 
removed for face validity (inconsistent with the rotavirus incu-
bation period).
Second, we conducted a systematic literature review adher-
ing to the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines to identify other rel-
evant rotavirus studies. A  full description of the search strat-
egy is provided in the Supplementary Appendix. In brief, we 
searched for papers published between January 1990 and 
February 2017 and publications in English, French, Spanish, 
and Polish. We excluded studies in which rotavirus positivity 
was not determined by EIA or quantitative polymerase chain 
reaction; nonhuman studies; nosocomial infection studies; 
studies without information on individuals aged <5  years; 
special populations such as human immunodeficiency virus–
infected patients; meta-analyses and systematic reviews report-
ing regional or global age distributions; and papers without an 
accessible full-text link. Two independent reviewers (M. H.-A., 
C, N. L.) screened abstracts and any ambiguity was resolved by 
a third reviewer (A. D.  C.). A  letter was sent by email to the 
investigators of all studies identified in the systematic review. 
Investigators were asked to provide anonymized data or com-
plete a standard data extraction table with counts by week of 
age up to 5.0 years. If the investigators did not respond before 
the end of August 2017 and no other study was available for that 
country, we extracted the age distribution reported in the pub-
lication. We included all country datasets that were obtained 
from a previously unpublished literature and database search 
conducted by Sanderson et al in 2012 [9]. This included articles 
published between 1990 and 2011.
All country datasets were combined into a central data-
base with a standard format and list of variables and analyzed 
together with the GRSN datasets. We cross-checked datasets 
identified through the literature search and GRSN to avoid data 
duplication. Prior to analyzing the datasets, we excluded stud-
ies that included <35 RVGE events, had known concerns about 
EIA quality, had <3 age bands <1 year of age, and did not cap-
ture cases from birth. We designed a tool to assess the risk of 
bias in randomized controlled trials and observational studies 
and assigned very low, low, or medium risk of bias to each coun-
try dataset. The risk of bias was scored against a list of 5 criteria 
(Supplementary Appendix).
Data Analysis
We fit a range of parametric distributions (gamma, Weibull, 
log-normal, log-logistic, Burr) to several GRSN datasets that 
were reported by day of age, and that represented the extreme 
range of younger and older age distributions globally. We fit 
age distributions using maximum likelihood estimation. The 
best-fitting distribution was chosen by comparing goodness-
of-fit statistics (Kolmogorov-Smirnov, Cramer–von Mises, 
Anderson-Darling) and goodness-of-fit criteria (Akaike infor-
mation criterion, Bayesian information criterion). For each 
country dataset, we calculated the best-fitting parameters of 
the chosen distribution. We generated summary tables with the 
median age, interquartile age range, and the cumulative propor-
tion of RVGE cases aged <5 years that were estimated to occur 
at different granular ages between birth and age 5.0 years. We 
reported the root mean squared error and mean absolute error 
for the parametric distribution fitted to each country dataset. 
All analyses were conducted using R version 3.4.1 using the 
following packages: polspline, nloptr, zoo, MASS, fitdistrplus, 
actuar, and mutil.
We assigned each of the 201 countries in the world to an 
under-5 mortality quintile (very low, low, medium, high, and 
very high) using 2010–2015 estimates of under-5 mortality as 
reported by the United Nations Population Division 2017 re-
vision [15]. We grouped all datasets according to the under-5 
mortality quintile of the country concerned, and calculated 
the median age and median best-fitting parameters for each 
stratum. We also ran a series of regression analyses to explore 
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which combinations of variables would best predict the me-
dian age and parameters of the chosen parametric distribution. 
To compare differences in rotavirus disease presentations, we 
plotted the full set of median ages reported for a given presenta-
tion against their respective 2010–2015 under-5 mortality rates. 
We fit a least-squares line of best fit for each presentation, re-
ported the R2 value, and compared the best-fitting lines.
We used ArcGIS mapping software to display the median age 
of rotavirus hospitalization estimated for each country in the 
world. If more than a single dataset was available for a country, 
we calculated the median age and median best-fitting parame-
ters of all datasets for that country. If no dataset was available, 
we assigned the median age of the country’s corresponding 
mortality stratum.
RESULTS
We identified 117 prevaccination datasets with rotavirus-pos-
itive events among children <5  years of age (6 datasets with 
community cases, 12 with clinic visits, 7 with emergency vis-
its, 92 with hospital admissions, and 0 with deaths) (Table 1; 
Figure 1). Around half of the country datasets (51/117) were 
rotavirus-positive cases identified through hospital-based sen-
tinel site surveillance from the GRSN (35 reported by day of 
age and 16 reported by month of age). The other half (66/117) 
were identified from the systematic literature review (n = 61) 
or obtained from the previously unpublished review (n  =  5). 
The 117 prevaccination datasets were taken from 47 studies 
with very low (n = 24), low (n = 12), and medium (n = 11) risk 
of bias.
Log-logistic age distributions had favorable goodness-of-fit 
statistics and criteria (Supplementary Figures 1 and 2), so were 
used to generate summary statistics on the age distribution of 
hospital admissions aged <5 years (Supplementary Tables 2 and 
3). The median age of RVGE hospital admission was 38 weeks 
(interquartile range [IQR], 25–58 weeks) in countries with very 
high child mortality, 43 weeks (IQR, 28–68 weeks) in coun-
tries with high child mortality, 46 weeks (IQR, 29–72 weeks) 
in countries with medium child mortality, and 65 weeks (IQR, 
40–107 weeks) in countries with low/very low child mortality 
(Figure 2). We collapsed the low and very low child mortality 
strata because they had a similar median age (67 weeks for very 
low and 63 weeks for low) and regression analyses showed there 
was no difference between the 2 strata (P = .234; Supplementary 
Table 5, regression model 5). In countries with very high child 
mortality, 69% of rotavirus-positive admissions in children 
aged <5 years were in the first year of life, with 3% by 10 weeks, 
8% by 15 weeks, and 27% by 26 weeks. There was considerable 
variation within each child mortality stratum. For example, in 
the very high child mortality stratum, the median age ranged 
from 29 weeks (IQR, 19–46 weeks) in Zambia to 50 weeks (IQR, 
30–81 weeks) in Ethiopia. Similarly, in the low/very low mortal-
ity stratum, the median age ranged from 35 weeks (IQR, 19–64 
weeks) in France to 101 weeks (IQR, 65–157 weeks) in Ukraine.
Globally, most countries with a low median age were in 
Africa (Figure 3). In general, the median age of rotavirus-posi-
tive hospital admissions decreased as child mortality increased 
(one-way analysis of variance; P < .0001), but there were notable 
outliers such as France and the Netherlands, where the median 
age was exceptionally low (35 and 48 weeks, respectively), and 
Mauritius and Ukraine, where the median age was exceptionally 
high (84 and 101 weeks, respectively). Regression models with 
more variables provided no substantive advantage over the sim-
ple stratification by under-5 mortality quintile (Supplementary 
Tables 4 and 5).
There were relatively few global datasets with age distribu-
tions for community cases, clinic visits, and emergency visits, 
and none for RVGE deaths that met our inclusion criteria. The 
median age for RVGE emergency visits was around 10 weeks 
younger than the median age for RVGE hospital admissions. 
The median age for RVGE clinic visits was around 5 weeks 
older than the median age for RVGE hospital admissions 
(Supplementary Tables 6–8). This pattern was consistent across 
settings with different under-5 mortality rates (Supplementary 
Figure 3).
DISCUSSION
We have gathered and synthesized a large amount of evidence 
on rotavirus age distributions globally. To our knowledge, 
Table 1. Number of Country Datasets Containing Rotavirus Gastroenteritis Age Distributions Before the Introduction of Rotavirus Vaccination, by Type of 
Presentation and Under-5 Mortality Quintile
Quintile for 2010–2015 Under-5 Mortality Rate
No. of Country Datasets (No. of Rotavirus-positive Cases)
Hospital Admissions Emergency Visits Clinic Visits Community Cases Total
Very low 13 (31 211) 3 (10 467) 3 (1552) 0 (0) 19 (43 230)
Low 8 (10 348) 2 (179) 1 (41) 0 (0) 11 (10 568)
Medium 14 (13 990) 0 (0) 1 (224) 1 (89) 16 (14 303)
High 31 (23 557) 2 (167) 3 (461) 4 (536) 40 (24 721)
Very high 26 (26 142) 0 (0) 4 (1066) 1 (71) 31 (27 279)
Total 92 (105 248) 7 (10 813) 12 (3344) 6 (696) 117 (120 101)
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this is the first systematic global study to estimate granular 
age distributions by country, mortality stratum, and level of 
care sought. We use statistically robust and standard methods 
to provide reproducible parametric age distributions for each 
country. We show that the median age of rotavirus disease 
varies between and within countries but tends to occur at a 
much younger age in higher-mortality settings. According to 
the basic principles of infectious disease dynamics, a younger 
Figure 1. Flowchart of the study selection process and data extraction. Some studies contained multiple datasets. Abbreviations: EIA, enzyme immunoassay; ELISA, 
enzyme-linked immunosorbent assay; GRSN, Global Rotavirus Surveillance Network; Pre-Vac, prevaccination; Post-Vac, postvaccination; RT-PCR, reverse-transcription poly-
merase chain reaction.
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average age of infection is likely to be associated with a higher 
force of infection. This is consistent with reported inci-
dence rates of rotavirus infection, which have been shown to 
peak at 5.5 months in Vellore, India (high mortality) and at 
20 months in Mexico City (medium mortality). However, in 
these sites the overall rate of infection and the age distribu-
tion of symptomatic RVGE cases were not substantially dif-
ferent [16]. This is probably because infections among Indian 
children were less likely to protect against subsequent disease, 
leading to several cases in older Indian children [17, 18]. This 
is consistent with the lower protection acquired from doses 
of rotavirus vaccination in higher-mortality settings [19]. 
Our analysis of a much larger number of settings has shown 
that the most severe RVGE cases (ie, those being admitted to 
hospital) tend to occur at younger ages in higher-mortality 
settings. We hypothesize that this is probably due to a higher 
force of infection and shorter intervals between repeat infec-
tions. There could also be important age-specific differences 
in the early management and treatment of RVGE in high-
er-mortality settings.
Our analysis relies heavily on the WHO GRSN database, 
which may include sentinel sites that are not fully representa-
tive of the country concerned. Importantly, healthcare-seeking 
behavior varies by country and age, and this may help to explain 
heterogeneities observed within each mortality stratum. For 
example, in some settings with high rates of private health-
care, children aged <1  year may be more likely to be treated 
outside of the regular sentinel surveillance system. In Hungary, 
Slovenia, and Ukraine, the median age of rotavirus-positive 
hospital admissions was 86, 88, and 101 weeks, respectively. 
This high median age might simply be a characteristic of rotavi-
rus in Central and Eastern Europe or may reflect other surveil-
lance peculiarities (eg, underrecruitment of younger patients 
or overrecruitment of mild RVGE cases). We analyzed the very 
low and low mortality strata without Ukraine, but that did not 
change the median age of 65 weeks. In other datasets, there may 
be a bias to younger ages. For example, we found a surprisingly 
low median age of hospital admission from multiple datasets in 
France (median age, 27–41 weeks) for reasons that are not clear.
We chose to fit parametric distributions rather than report the 
actual age distributions observed in each study. This required 
an assumption to be made about the standard functional form 
of the distribution. However, our parametric fitting approach 
(1) provides a function that can be easily reproduced by others; 
(2) avoids the issue of heaping—that is, the tendency to report 
cases at exactly 1.0 years, 2.0 years, etc, an issue that has been 
Figure 2. Age distributions of rotavirus-positive hospital admissions by under-5 mortality strata.
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Figure 3. Estimated and extrapolated prevaccination median age of rotavirus-positive hospital admissions in children aged <5 years, by country. Lighter red represents 
younger median age and darker red represents older median age. If >1 study was conducted within a country, the median of median ages was used. If no data were available 
for a country, the median age was extrapolated (indicated by diagonal shading) using the median age of the under-5 mortality stratum. Abbreviations: GRSN, Global Rotavirus 
Surveillance Network; RVGE, rotavirus gastroenteritis. The map is reprinted with permission from the World Health Organization.
evident in many of the datasets because of a reporting artefact; 
(3) smooths distributions based on small (noisy) samples; and 
(4) allows standard reporting of the proportion of RVGE cases 
that occur at specific ages, for example, the proportion of cases 
occurring before the first dose of rotavirus vaccine at 6 weeks, 
or before vaccine age restrictions are applied at 15 weeks. We 
also explored nonparametric smoothing approaches. We used 
kernel density estimation, with default Gaussian smoothing. 
However, heaping was evident in some of the datasets, and areas 
of density below zero were common. One way to avoid this is to 
truncate the density at zero, but this introduces a bias in the dis-
tribution and creates an implausible cliff-edge at zero in some 
datasets. Another way to avoid this is to use logspline density 
estimation, with the lower bound set to zero. This worked well 
for some datasets but not others and required manual adjust-
ment to the number and location of knots, so it was not practi-
cal as a standardized approach.
We obtained many datasets on rotavirus-positive hospital 
admissions but few on other presentations. No datasets with 
rotavirus-positive deaths met our inclusion criteria because they 
had <35 deaths, and it was very difficult to ascertain whether 
the deaths were entirely attributable to rotavirus. Compared to 
hospital admissions, we found a higher median age for clinic 
visits and a younger median age for emergency visits, but this 
was based on very few data points and more data would be 
needed to confirm this.
In conclusion, the median age of rotavirus disease in children 
aged <5 years varies between and within countries but tends to 
be younger in higher-mortality settings. The age distributions 
presented in this article should provide information that is crit-
ical for assessing the potential benefits of alternative rotavirus 
vaccination schedules in different countries, and for monitoring 
the impact of rotavirus vaccines.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding author.
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